Browse News
Filter News
Found 145 articles
-
Anebulo Pharmaceuticals Announces New CEO
10/6/2023
Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication, announced that Richie Cunningham has been appointed as Anebulo’s Chief Executive Officer, replacing Simon Allen.
-
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
3/2/2023
Syros Pharmaceuticals today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.
-
Eagle Pharmaceuticals Provides Business Update and Guidance for 2023
1/10/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023.
-
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
11/14/2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update.
-
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
9/16/2022
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million.
-
Syros and Tyme Technologies Announce Stockholder Approval of Merger
9/15/2022
Syros Pharmaceuticals, Inc., a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022.
-
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
8/9/2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update.
-
As the global life sciences industry slows down, companies are gathering money through means other than VC funding. BioSpace shines a light on some of these recent transactions.
-
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7/5/2022
Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs.
-
Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer
6/28/2022
Elevar Therapeutics, Inc., today announced the hiring of Jan M. Van Tornout, M.D., MSc., as chief medical officer, and Gordon Schooley, Ph.D., as chief regulatory officer.
-
TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results-- $84.0 million in cash and marketable securities as of March 31, 2022 --
5/25/2022
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022.
-
Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors
5/5/2022
Organogenesis Holdings Inc. announced the appointments of Michele Korfin and Gilberto Quintero, Ph.D. to the Company’s Board of Directors, effective May 3, 2022.
-
HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer
5/2/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately.
-
South Rampart Pharma Appoints Robert Dickey, MBA, as Chief Financial Officer
3/31/2022
South Rampart Pharma today announced the appointment of Robert Dickey, MBA, as its Chief Financial Officer.
-
TYME Technologies, Inc. Announces Exploration of Strategic Options
3/29/2022
TYME Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.
-
TYME Technologies, Inc. Announces Changes to its Board of Directors
3/25/2022
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced changes to its Board of Directors.
-
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022
3/9/2022
TYME Technologies, Inc. today announced the availability of the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer,” which was submitted by researchers from Georgetown University.
-
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results
3/7/2022
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2021.
-
AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer
3/3/2022
AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, announced the appointment of Robert Dickey IV, as its Chief Financial Officer.
-
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results
2/11/2022
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third fiscal quarter ended December 31, 2021.